New Risk • May 17
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$35m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (409% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$35m). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$89.7m market cap). Breakeven Date Change • May 15 The 7 analysts covering Pelthos Therapeutics previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 78% per year to 2027. The company is expected to make a profit of US$32.9m in 2028. Average annual earnings growth of 71% is required to achieve expected profit on schedule.
Annuncio • May 01
Pelthos Therapeutics Inc. to Report Q1, 2026 Results on May 14, 2026 Pelthos Therapeutics Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 14, 2026 Annuncio • Apr 12
Pelthos Therapeutics Inc. Announces Chief Financial Officer Transition Pelthos Therapeutics Inc. announced John M. Gay has been appointed Chief Financial Officer effective April 10, 2026. Mr. Gay succeeds Francis Knuettel II, who served as Pelthos’ Chief Financial Officer since July 2025. Mr. Gay has served as Senior Vice President, Finance & Accounting at Pelthos since 2025. He has more than 25 years of public company finance and accounting experience. Prior to joining Pelthos, he served as Chief Financial Officer of LNHC Inc. (then, a wholly owned subsidiary of Ligand Pharmaceuticals Inc.) and in senior finance roles at several publicly traded companies, including Furiex Pharmaceuticals, which was ultimately acquired by Forest Laboratories. He previously held roles at Deloitte and Arthur Andersen. Annuncio • Mar 31
Pelthos Therapeutics Inc. Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain Pelthos Therapeutics Inc. announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Channel Pharmaceutical Corporation owns the rights to CT2000 and its NaV1.7 inhibitor pipeline and is conducting the clinical work through its Australian subsidiary. The placebo-controlled Phase 1b/2a clinical trial will evaluate the safety and clinical efficacy of CT2000 eye drop formulation in patients with moderate to severe dry eye disease with chronic eye pain. The trial will be an adaptive design with a Phase 1 ascending dose study (with acute ocular pain measures) and a Phase 2a maximum tolerated dose study with a 28-day dosing period. Results are anticipated at the end of 2026. In May 2025, Channel announced that it achieved its predefined endpoints in two pre-clinical animal models of its CT2000 eye drop formulations for the treatment of acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease. CT2000 is a novel ophthalmic formulation of Channel’s CC8464 that targets the sodium ion-channel known as NaV1.7, a key factor in the propagation of pain signals in peripheral nerves. NaV1.7 channels are widely expressed in the corneal nerve plexus, making it an attractive target for treating eye pain. Eye pain may occur with various conditions, including severe dry eye disease, trauma and surgery. Existing therapies for eye pain, including steroids, topical non-steroidal anti-inflammatory agents, lubricants, and local anesthetics, are limited in their effectiveness and/or limited in the duration that they may be prescribed because of safety issues. It is estimated that the global chronic ocular pain market will reach $5.3 billion by 2032. Major Estimate Revision • Mar 26
Consensus EPS estimates fall by 99% The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$5.96 to -US$11.85 per share. Revenue forecast unchanged at US$61.6m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$58.33. Share price was steady at US$22.74 over the past week. Annuncio • Mar 09
Pelthos Therapeutics Inc. to Report Q4, 2025 Results on Mar 19, 2026 Pelthos Therapeutics Inc. announced that they will report Q4, 2025 results on Mar 19, 2026 Breakeven Date Change • Mar 08
Forecast breakeven date pushed back to 2028 The 6 analysts covering Pelthos Therapeutics previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of US$26.6m in 2028. Average annual earnings growth of 53% is required to achieve expected profit on schedule. Major Estimate Revision • Mar 03
Consensus EPS estimates fall by 10% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$18.0m to US$16.9m. Losses expected to increase from US$13.14 per share to US$14.51. Biotechs industry in the US expected to see average net income decline 8.5% next year. Consensus price target down from US$60.40 to US$58.00. Share price rose 4.0% to US$24.16 over the past week. Annuncio • Jan 13
Pelthos Therapeutics Inc. announced that it expects to receive $50 million in funding Pelthos Therapeutics Inc. announced that it has entered into a Venture Loan and Security Agreement with new lender Horizon Technology Finance Corporation, a fund managed by, Horizon Technology Finance Management, LLC for an aggregate principal amount of up to $50 million on January 12, 2026. The company has borrowed $30 million of Term Loans on the same date. The remaining $20 million of Terms Loans may be borrowed under the Loan Agreement upon the achievement by the Company of certain milestones set forth in the Loan Agreement. The Loan Agreement accrue interest at a rate equal to the prime rate plus 3.75% with the prime rate having a floor of 6.75%. The Term Loans are repayable in monthly interest-only payments from March 1, 2026 until February 1, 2029. After the expiration of the Interest-Only Payment Period, beginning on March 1, 2029, the Term Loans will be repayable in 24 equal monthly payments of principal and accrued interest until maturity. if the Borrowers achieve a trailing twelve-month consolidated net revenue of at least $75.0 million, the Term Loans will be repayable in monthly interest-only payments from March 1, 2026 until February 1, 2030. After the expiration of the Extended Interest-Only Payment Period, the Term Loans will be repayable in 12 equal monthly payments of principal and accrued interest until maturity. The Term Loans will mature on January 31, 2031. The company paid a commitment fee in the amount of $300,000 on the Closing Date. The company will pay an additional commitment fee in the amount of 1.0% of the principal amount of the last six Term Loans concurrently with the funding of those six Term Loans. Recent Insider Transactions • Nov 28
Independent Director recently sold US$280k worth of stock On the 25th of November, Ezra Friedberg sold around 10k shares on-market at roughly US$28.03 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Annuncio • Nov 17
Pelthos Therapeutics Inc., Annual General Meeting, Dec 17, 2025 Pelthos Therapeutics Inc., Annual General Meeting, Dec 17, 2025. Annuncio • Nov 08
Pelthos Therapeutics Inc. announced that it has received $18 million in funding from Ligand Pharmaceuticals Incorporated Pelthos Therapeutics Inc. has entered into entered into a securities purchase agreement with certain investors, including Ligand Pharmaceuticals and issued $18,000,000 senior secured notes which are convertible into shares of the Company’s common stock, par value $0.0001 per share on November 6, 2025. The notes have interest at a rate of 8.5% per annum, payable quarterly in arrears. The Notes will mature on November 6, 2027, unless earlier repurchased, redeemed or converted into shares of common stock in accordance with their terms. The Notes will be convertible at an initial conversion price of $34.442. Annuncio • Nov 05
Pelthos Therapeutics Inc. to Report Q3, 2025 Results on Nov 13, 2025 Pelthos Therapeutics Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 13, 2025 Annuncio • Oct 10
Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum Pelthos Therapeutics Inc. announced the launch of Moms against Molluscum, a movement to unite mothers, parents, and other caregivers navigating molluscum contagiosum. The Moms Against Molluscum movement encourages people managing this highly contagious skin infection to visit Moms AgainstMolluscum.com to share their stories and access information about new treatment options, including ZELSUVMI™? (berdazimer) topical gel, 10.3%. Molluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application and can be used to treat molluscum infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infection. New Risk • Aug 28
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 428% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-US$6.5m). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (428% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$72.2m market cap). Annuncio • Jul 10
Pelthos Therapeutics Launches Zelsuvmi™? (Berdazimer) Topical Gel 10.3%, the First and Only Fda-Approved At-Home Treatment for Molluscum Contagiosum Pelthos Therapeutics Inc. announced the launch of ZELSUVMI™? (berdazimer) topical gel, 10.3%, for the treatment of molluscumcontagiosum (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI received a novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections, a highly contagious viral skin condition. The once-daily prescription medication is effective, well tolerated, and convenient for at-home or on-the-go application and can be used to treat infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI was studied in the largest randomized clinical trial for the treatment of mollusum. The trial was a multicenter, randomized, double-blind, vehicle controlled, parallel-group, Phase 3 study of the efficacy and safety of ZELSUVMI in 891 patients. These patients have waiting a long time for an at-home treatment option. ZELSUVMI is now commercially available through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies via prescription. New Risk • May 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$4.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.4m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-US$4.2m). Earnings have declined by 57% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$6.47m market cap). Annuncio • May 15
Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using Its Nav1.7 Inhibitor in Multiple Preclinical in Vivo Models Channel Therapeutics Corporation announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company's eye drop formulations ("CT2000") for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease. In the first trial, rabbits were treated with capsaicin (i.e., Pepper spray) to mimic an acute ocular insult in a common, validated model for acute eye pain studies. Following the capsaicin treatment, the rabbits were treated with CT2000, which was dosed four times over a 24-hour period. Pain was measured by the number of paw wipes over 60 seconds (paw wipes are a recognized surrogate of eye pain in animal models). The results showed that CT2000 significantly reduced the number of paw wipes within 15 minutes of administration of capsaicin and that CT2000 continued to show efficacy over a 60-minute period following administration. This eye pain model was only validated for a short duration, with the results summarized in the following graph: Trial Two: In the second trial, benzalkonium chloride was instilled in mice eyes over a multiday period to create a model of dry eye disease (the study was repeated twice). BAC is a detergent that irritates the eyes and simulates dry eye disease. It is this existing market that the Company intends to target with CT2000, in addition to the post operative pain market with recently announced data on the efficacy of Depot formulation, which will be developed for use in post operative nerve blocks. Annuncio • Dec 19
Channel Therapeutics Announces Positive Efficacy Data for A Depot Formulation of A NaV1.7 Inhibitor in A Preclinical in Vivo Nerve Block Model Channel Therapeutics Corporation, announced that it achieved its endpoints in two pre-clinical in vivo models of the Company’s nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration. About the trial The Company performed a thermal hyperalgesia test in rodents with a placebo arm, bupivacaine arm and four arms of the main formulations of the Company’s molecule. The Company also performed a mechanical allodynia test in rodents with the same arms as above. For both models, the drugs were administered as a sciatic nerve block. All four Company formulations showed a depot effect in excess of four days, an improvement over bupivacaine, the current standard of care. Results The results of the thermal hyperalgesia results are shown in the chart below. After thirty minutes, three of the four formulations showed materially better efficacy than bupivacaine, with each of the three being statistically superior to placebo for more than two days longer than bupivacaine. One of the formulations remained statistically superior to placebo for more than four days. Further, as NaV1.7 does not have an impact on mobility, this approach may offer a better option for post-surgical physical therapy as current nerve block therapies cause temporary paralysis in the affected area. Similarly for the mechanical allodynia test results, three of the four formulations showed statistically better efficacy for a longer duration of time than bupivacaine. The mechanical allodynia test is shorter in duration, reflecting the subject’s innate swift recovery rate to surgical incisions. Nonetheless, the results mirrored the successful results set forth with the thermal hyperalgesia test. Annuncio • Nov 21
Channel Therapeutics Corporation Provides Therapeutic Program Update Channel Therapeutics Corporation Provided Therapeutic Program Update. Depot Program for Postoperative Nerve Blocks – the Company showed a sustained release of drug over a 96-hour period in animals and is currently performing efficacy studies in animals, with results expected imminently. Eye Pain Program – the eye drops were well tolerated in an animal study and the Company is performing efficacy studies in animal models of eye pain with toxicology studies starting shortly. The results of the efficacy studies are expected in the coming weeks and the toxicology data is expected in late first quarter of 2025. The Company expects to commence Phase II human proof of concept studies in second quarter of 2025, with a readout by the end of 2025. Chronic Pain – the Company is exploring program-specific financing for this program with expectations that the program will be kicked off in first quarter of 2025. New Risk • Nov 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.5m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$1.4m). Earnings have declined by 73% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$3.87m market cap). Annuncio • Oct 29
Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain Chromocell Therapeutics Corporation announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company's novel NaV1.7 molecule for treating chronic pain and eye pain. There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product. The Company believes there are strong synergies between the programs and is building a suite of related products to address multiple different types of pain and methods of delivery, with a drug that has shown no addictive properties in 4 Phase I trials. With these programs, the Company hopes to reduce usage of opioids and other sub-optimal drugs in various indications and expects to be able to take advantage of certain NOPAIN Act provisions if the drugs are approved by the FDA. Board Change • Sep 30
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. Independent Director Ezra Friedberg is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Annuncio • Sep 10
Chromocell Therapeutics Corporation, Annual General Meeting, Oct 22, 2024 Chromocell Therapeutics Corporation, Annual General Meeting, Oct 22, 2024. Annuncio • Aug 08
Chromocell Therapeutics Corporation (NYSEAM:CHRO) announces an Equity Buyback for $0.25 million worth of its shares. Chromocell Therapeutics Corporation (NYSEAM:CHRO) announces a share repurchase program. Under the program, the company will repurchase up to $0.25 million worth of its shares. The plan is valid till December 31, 2024. Annuncio • Apr 02
Chromocell Therapeutics Corporation announced delayed annual 10-K filing On 04/01/2024, Chromocell Therapeutics Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Mar 21
Chromocell Therapeutics Corporation Announces Formal Launch of Eye Pain Treatment Program Chromocell Therapeutics Corp. announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler. The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications. Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae. Chronic eye pain indications include autoimmune diseases, dry eye and neuropathic etiologies. Chromocell’s platform uniquely targets the NaV1.7 channels on the cornea with the ability to treat all eye pain indications. Annuncio • Mar 20
Chromocell Therapeutics Corp. Appoints Frank Knuettel, Interim CEO, as Permanent CEO Chromocell Therapeutics Corp. announced that its interim CEO Frank Knuettel, has been appointed as the Company’s permanent CEO. Mr. Knuettel was previously appointed Interim CEO in July 2023, while currently serving as the Company’s CFO, a role he will continue to fill for the near future. Board Change • Feb 16
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 2 experienced directors. No highly experienced directors. Independent Director Ezra Friedberg is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Annuncio • Feb 16
Chromocell Therapeutics Corporation has completed an IPO in the amount of $6.6 million. Chromocell Therapeutics Corporation has completed an IPO in the amount of $6.6 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,100,000
Price\Range: $6
Transaction Features: Sponsor Backed Offering 
